Methylene blue-photoinactivated plasma vs. flesh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura

Vox Sanguinis

Volumn 86, Issue 4, 2004, Pages 246-251

  Alvarez Larran A ^a   Del Rio J ^b   Ramirez C ^c   Albo, C ^d   Pena F ^e   Campos, A ^f   Cid, J ^g   Muncunill, J ^h   Sastre, J L ⁱ   Sanz, C ^a   Pereira, A ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b Hospital da Barbanza   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d HOSPITAL XERAL CÍES   (Spain)

^e HOSPITAL DO MEIXOEIRO   (Spain)

^f Instituto de Salud Carlos III   (Spain)

^g BANC DE SANG I TEIXITS   (Spain)

^h HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

ⁱ Hospital Cristal Pinor   (Spain)

Author keywords

Plasma exchange; Thrombotic thrombocytopenic purpura

Indexed keywords

CORTICOSTEROID; FRESH FROZEN PLASMA; METHYLENE BLUE; VINCRISTINE;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FATALITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHYLENE BLUE PHOTOINACTIVATED PLASMA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PLASMA; PLASMAPHERESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SAFETY; SPLENECTOMY; SUBSTITUTION THERAPY; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; METHYLENE BLUE; MIDDLE AGED; PHOTOCHEMISTRY; PLASMA; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRUS INACTIVATION;

EID: 3142515949     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0042-9007.2004.00506.x     Document Type: Article

References (28)

1. Byrnes JJ, Moake JL: Thrombotic thrombocytopenic purpura and the haemolytic-uraemic syndrome: evolving concepts of pathogenesis and therapy. Clin Haematol 1986; 15:413-442
2. Amorosi EL, Ultmann JE: Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 1966; 45:139-159
3. Rock G, Porta C, Bobbio-Pallavicini E: Thrombotic thrombocytopenic purpura treatment in year 2000. Haematologica 2000; 85:410-419
4. Bianchi V, Robles R, Alberio L, Furlan M, Lammle B: Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100:710-713
5. Pamphilon D: Viral inactivation of fresh frozen plasma. Br J Haematol 2000; 109:680-693
6. Horowitz MS, Pehta JC: SD Plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang 1998; 74:231-235
7. Moake J, Chintagumpala M, Turner N, McPherson P, Nolasco L, Steuber C, Santiago-Borrero P, Horowitz M, Pehta J: Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood 1994; 84:490-497
8. Harrison CN, Lawrie AS, Iqbal A, Hunter A, Machin SJ: Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura. Br J Haematol 1996; 94:756-758
9. Evans G, Llewelyn C, Luddington R, Baglin TP, Williamson LM: Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura. Clin Lab Hematol 1999; 21:119-123
10. de la Rubia J, Arriaga F, Linares D, Larrea L, Carpio N, Marty ML, Sanz MA: Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2001; 114:721-723
11. Rose M, Eldor A: High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients. Am J Med 1987; 83:437-444
12. Pereira A, Mazzara R, Monteagudo J, Sanz C, Puig L, Martinez A, Ordinas A, Castillo R: Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol 1995; 70:319-323
13. Lambrecht B, Mohr H, Knuver-Hopf J, Schmitt H: Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 1991; 60: 207-213
14. Nowak-Harnau S, Wagner FF, Flegel WA: Completely converting a national blood supply to the use of safer plasma. Transfusion 2001; 41:1172-1173
15. Inada Y, Hessel B, Blomback B: Photooxidation of fibrinogen in the presence of methylene blue and its effect on polymerization. Biochim Biophys Acta 1978; 532:161-170
16. Henschen-Edman AH: Photo-oxidation of histidine as a probe for aminoterminal conformational changes during fibrinogen-fibrin conversion. Cell Mol Life Sci 1997; 53:29-33
17. Zeiler T, Riess H, Wittmann G, Hintz G, Zimmermann R, Muller C, Heuft HG, Huhn D: The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma. Transfusion 1994; 34:685-689
18. Atance R, Pereira A, Ramirez B: Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 2001; 41:1548-1552
19. Martinez C, Muñiz-Diaz E, Pastoret C, Sánchez I, Ramos A, Ciebdones M, Montero A, Madoz P: Experience with methylene blue virus-inactivated plasma in the tretment of thrombotic thrombocytopenic purpura. Vox Sang 2000; 78:P224 (Abstr.)
20. Lara PN, Coe TL, Zhou H, Fernando L, Holland PV, Wun T: Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Am J Med 1999; 107:573-579
21. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura - Canadian Apheresis Study Group. N Engl J Med 1991; 325:393-397
22. George JN: How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000; 96: 1223-1229
23. Liu ET, Linker CA, Shuman MA: Management of treatment failures in thrombotic thrombocytopenic purpura. Am J Hematol 1986; 23:347-361
24. Sarode R, Gottschall JL, Aster RH, McFarland JG: Thrombotic thrombocytopenic purpura: early and late responders. Am J Hematol 1997; 54:102-107
25. Onundarson PT, Rowe JM, Heal JM, Francis CW: Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura: a 10-year experience at a single institution. Arch Intern Med 1992; 152:791-796
26. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B: von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339:1578-1584
27. Cardigan R, Allford S, Williamson L: Levels of von Willebrand factor-cleaving protease are normal in methylene blue-treated fresh-frozen plasma. Br J Haematol 2002; 117:253-254
28. Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El Harake MA, Raskob GE: ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102:60-68